Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection

Currently, the only approved hepatitis C virus (HCV) treatment for children aged <12 years is pegylated interferon plus ribavirin. In an open‐label study, we evaluated the safety and efficacy of sofosbuvir plus ribavirin for 12 weeks in children aged 3 to <12 years chronically infected with ge...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Hepatology
Asıl Yazarlar: Rosenthal, Philip, Schwarz, Kathleen B., Gonzalez‐Peralta, Regino P., Lin, Chuan‐Hao, Kelly, Deidre A., Nightingale, Scott, Balistreri, William F., Bansal, Sanjay, Jonas, Maureen M., Massetto, Benedetta, Brainard, Diana M., Hsueh, Chia‐Hsiang, Shao, Jiang, Parhy, Bandita, Davison, Suzanne, Feiterna‐Sperling, Cornelia, Gillis, Lynette A., Indolfi, Giuseppe, Sokal, Etienne M., Murray, Karen F., Wirth, Stefan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2019
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7004103/
https://ncbi.nlm.nih.gov/pubmed/31222783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.30821
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller